Ernexa Therapeutics Inc. (ERNA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ernexa Therapeutics Inc., a Delaware corporation, on September 14, 2026. The report discloses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial statements or performance data.
Material Changes
The material change reported is the appointment of Robert J. Spiegel, M.D., as a member of the Board of Directors, effective immediately on September 14, 2026. Dr. Spiegel will serve until his successor is elected or until earlier death, resignation, or removal.
Guidance, Outlook, and Management Commentary
Dr. Spiegel's compensation will be determined in accordance with the Company's Board of Directors Compensation Plan adopted on August 15, 2026, as detailed in the Form 10-Q filed on August 6, 2026. The filing confirms there are no undisclosed arrangements or family relationships between Dr. Spiegel and other directors or officers, and no reportable transactions exist between the Company and Dr. Spiegel under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Robert J. Spiegel, M.D., was appointed to the Board of Directors effective September 14, 2026.
- Compensation is governed by the Board Compensation Plan adopted on August 15, 2026.
- No family relationships or undisclosed arrangements exist between the new director and current management.
- The filing contains no financial performance data; investors should refer to the Form 10-Q for the period ended June 30, 2026, for financial context.